Initial symptoms and three months follow-up after acute COVID-19 in outpatients: An international prospective cohort study.
COVID-19
daily activities
lingering symptoms
long-COVID
post-COVID
primary care
Journal
The European journal of general practice
ISSN: 1751-1402
Titre abrégé: Eur J Gen Pract
Pays: England
ID NLM: 9513566
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
medline:
8
6
2023
pubmed:
20
1
2023
entrez:
19
1
2023
Statut:
ppublish
Résumé
Most studies on long-term follow-up of patients with COVID-19 focused on hospitalised patients. No prospective study with structured follow-up has been performed in non-hospitalised patients with COVID-19. To assess long-COVID and post-COVID (WHO definition: symptomatic at least 12 weeks), describe lingering symptoms, their impact on daily activities, and general practice visits and explore risk factors for symptom duration in outpatients. A prospective study of adult outpatients with confirmed SARS-CoV-2 infection and symptoms consistent with COVID-19 in 11 European countries, recruited during 2020 and 2021 from primary care and the community. Structured follow-up by phone interviews (symptom rating, symptom impact on daily activities and general practice visits) was performed at weeks 2, 4, 8, and 12 by study personnel. Data was analysed descriptively by using correlation matrixes and Cox regression. Of 270 enrolled patients, 52% developed long-COVID and 32% post-COVID-syndrome. When only considering the presence of moderate or (very) severe symptoms at weeks 8 and 12, these percentages were 28% and 18%, respectively. Fatigue was the most often reported symptom during follow-up. The impact of lingering symptoms was most evident in sports and household activities. About half (53%) had at least one general practice contact during follow-up. Obese patients took twice as long to return to usual health (HR: 0.5, 95%CI: 0.3-0.8); no other risk profile could predict lingering symptoms. Long-COVID and post-COVID are also common in outpatients. In 32%, it takes more than 12 weeks to return to usual health.
Sections du résumé
BACKGROUND
UNASSIGNED
Most studies on long-term follow-up of patients with COVID-19 focused on hospitalised patients. No prospective study with structured follow-up has been performed in non-hospitalised patients with COVID-19.
OBJECTIVES
UNASSIGNED
To assess long-COVID and post-COVID (WHO definition: symptomatic at least 12 weeks), describe lingering symptoms, their impact on daily activities, and general practice visits and explore risk factors for symptom duration in outpatients.
METHODS
UNASSIGNED
A prospective study of adult outpatients with confirmed SARS-CoV-2 infection and symptoms consistent with COVID-19 in 11 European countries, recruited during 2020 and 2021 from primary care and the community. Structured follow-up by phone interviews (symptom rating, symptom impact on daily activities and general practice visits) was performed at weeks 2, 4, 8, and 12 by study personnel. Data was analysed descriptively by using correlation matrixes and Cox regression.
RESULTS
UNASSIGNED
Of 270 enrolled patients, 52% developed long-COVID and 32% post-COVID-syndrome. When only considering the presence of moderate or (very) severe symptoms at weeks 8 and 12, these percentages were 28% and 18%, respectively. Fatigue was the most often reported symptom during follow-up. The impact of lingering symptoms was most evident in sports and household activities. About half (53%) had at least one general practice contact during follow-up. Obese patients took twice as long to return to usual health (HR: 0.5, 95%CI: 0.3-0.8); no other risk profile could predict lingering symptoms.
CONCLUSION
UNASSIGNED
Long-COVID and post-COVID are also common in outpatients. In 32%, it takes more than 12 weeks to return to usual health.
Identifiants
pubmed: 36655704
doi: 10.1080/13814788.2022.2154074
pmc: PMC10249456
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2154074Références
BMJ. 2022 Jan 20;376:o158
pubmed: 35058230
NPJ Vaccines. 2022 Aug 26;7(1):101
pubmed: 36028498
Lancet Infect Dis. 2022 Jan;22(1):43-55
pubmed: 34480857
Int J Infect Dis. 2022 Mar;116:38-42
pubmed: 34971823
JAMA Netw Open. 2021 Oct 1;4(10):e2128568
pubmed: 34643720
BMJ. 2021 Dec 29;375:e065834
pubmed: 34965929
MMWR Morb Mortal Wkly Rep. 2020 Jul 31;69(30):993-998
pubmed: 32730238
EClinicalMedicine. 2021 Aug;38:101019
pubmed: 34308300
Environ Res. 2022 Jun;209:112816
pubmed: 35093310
BJGP Open. 2022 Aug 30;6(2):
pubmed: 34920989
Nat Med. 2021 Apr;27(4):626-631
pubmed: 33692530
Front Public Health. 2021 Jan 14;8:561264
pubmed: 33520906
Front Public Health. 2021 Jan 15;8:582932
pubmed: 33520910